Affected Products
A. ACCESS SYSTEM - UNCONJUGATED ESTRIOL ASSAY
B. UNICEL DXI 600 ACCESS IMMUNOASSAY SYSTEM - UNCONJUGATED ESTRIOL ASSAY
C. UNICEL DXI 800 ACCESS IMMUNOASSAY SYSTEM - UNCONJUGATED ESTRIOL ASSAY
Customer feedback has helped Beckman Coulter identify and characterize the potential for higher than expected Bovine-ALP associated interference in patient samples tested with the access uE3 assay, for the affected lots. An internal investigation of ~300 samples confirmed that up to 3% of patient samples may demonstrate Bovine-ALP associated interference. The frequency and mechanism of Bovine-ALP associated interference is specific to the access uE3 assay. This interference is not associated with patient sample endogenous ALP levels.
Based on the internal investigation performed on ~300 samples, Bovine-ALP associated interference could increase serum sample uE3 concentrations by:
-
a mean of 50% (range 33%-77%) in samples with uE3 concentrations >1.5 ng/mL.
-
a mean of 0.53 ng/mL (range 0.42-0.70 ng/mL) in samples with uE3 concentrations ?1.5 ng/mL.
A falsely elevated uE3 test result can lead to inaccurately classifying the relative risk of chromosomal anomalies-such as trisomy 21 and 18-in patient samples undergoing triple and quad prenatal screening.
Second trimester prenatal screening includes Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), unconjugated estriol (uE3) and inhibin A. Only uE3 is affected by the issue.